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Abstract
Introduction: Systemic Lupus Erythematosus (SLE) shows a spectrum of clinical manifestations that complicate its diagnosis,
treatment and research. This variability is likely related with environmental exposures and genetic factors among which
known SLE susceptibility loci are prime candidates. The first published analyses seem to indicate that this is the case for
some of them, but results are still inconclusive and we aimed to further explore this question.
Methods: European SLE patients, 1444, recruited at 17 centres from 10 countries were analyzed. Genotypes for 26 SLE
associated SNPs were compared between patients with and without each of 11 clinical features: ten of the American
College of Rheumatology (ACR) classification criteria (except ANAs) and age of disease onset. These analyses were adjusted
for centre of recruitment, top ancestry informative markers, gender and time of follow-up. Overlap of samples with previous
studies was excluded for assessing replication.
Results: There were three new associations: the SNPs in XKR6 and in FAM167A-BLK were associated with lupus nephritis
(OR= 0.76 and 1.30, Pcorr= 0.007 and 0.03, respectively) and the SNP of MECP2, which is in chromosome X, with earlier age of
disease onset in men. The previously reported association of STAT4 with early age of disease onset was replicated. Some
other results were suggestive of the presence of additional associations. Together, the association signals provided support
to some previous findings and to the characterization of lupus nephritis, autoantibodies and age of disease onset as the
clinical features more associated with SLE loci.
Conclusion: Some of the SLE loci shape the disease phenotype in addition to increase susceptibility to SLE. This influence is
more prominent for some clinical features than for others. However, results are only partially consistent between studies
and subphenotype specific GWAS are needed to unravel their genetic component.
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Introduction
Systemic Lupus Erythematosus shows a wide spectrum of
clinical manifestations and laboratory findings that complicate its
diagnosis, treatment and research [1,2]. We do not know the
causes of this variability, but likely contributing elements are
environmental exposures and genetic factors. Understanding the
relationships between these factors and the SLE clinical features
will help elucidate disease mechanisms and could provide the basis
for a classification of patients in more homogeneous subgroups.
Many associations between genetic polymorphisms and the
presence of specific SLE clinical features have been reported, but
they have not yet reached a high degree of confidence [3,4,5]. This
situation is similar to what had happened in relation to SLE
susceptibility until 2008 when the first SLE GWAS were
published. Now, there are about 30 loci that are consistently
associated with SLE susceptibility [6,7,8]. These loci are prime
candidates for having a predisposing effect for specific SLE clinical
features. The first analyses seem to indicate that this is the case for
some of them [9,10,11,12,13,14,15], but results are still inconclu-
sive. For example, the rs7574865 SNP in STAT4 has been
associated with a severe SLE phenotype defined by nephritis, age
at diagnosis ,30 years old, immunologic disorder (and, specifi-
cally, double-stranded DNA autoantibodies) and absence of oral
ulcers [10]. The association with immunologic disorder (and anti-
dsDNA) and an increase in nephritis prevalence were also reported
in two other studies, but not the associations with early onset or
lack of oral ulcers [9,13]. In contrast, a fourth study has reported
protection from oral ulcers but not association with any of the
other subphenotypes [14].
Herein, we have analyzed the association with SLE clinical
features of 26 SNPs that tag SLE susceptibility loci in 1444
European patients. Significant associations of renal involvement
with XKR6 and FAM167A-BLK SNPs and of earlier age of disease
onset and the MECP2 SNP in men were found. In addition, other
weak signals of association were detected that together with
concordant previous results obtained in non-overlapping samples
suggest a wider involvement of the susceptibility loci in shaping
some aspects of the SLE phenotype.
Materials and Methods
Ethic Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All subjects provided their written
informed consent as approved by the respective ethical committees
and the overall study was approved by the Comite Etico de
Investigacion Clinica de Galicia.
Clinical and Genotype Data
Patients used in this study have already been described [16,17].
Briefly, 17 recruiting centres from 10 European countries were
asked for about 100 SLE patients according with ACR criteria
[18], all of them with uniform ancestry from the country of
recruitment. Clinical characteristics of the patients were obtained
at the same time. They included the ACR classification criteria,
gender, age of disease onset, and time of follow-up. Genotypes of
26 SNPs tagging SLE loci indentified in large studies
[19,20,21,22,23,24,25,26,27,28] were available to us from previ-
ous studies [16,29,30]. They include 2 SNPs tagging the risk and
the protective haplotypes of IRF5 [29], 10 tag SNPs for 10 SLE
loci [16], and the 14 tag SNPs in 12 SLE loci [30]. In addition,
genotypes of six (rs6730157, rs382259, rs4988235, rs12203592,
rs354690 and rs12913832) top ancestry informative markers
(AIM) have also been obtained previously [17]. The three first
are the most informative AIMs in differentiating Northern from
Southern European subpopulations, and rs12203592 and
rs354690 are the two AIMs more informative for East-West
differentiation, identified in a study analyzing 300 000 SNPs in
4000 European subjects [31]. Results from rs4988235 were not
used for analysis because it was largely redundant with rs6730157
in our samples (r2 = 0.87). rs12913832 is a SNP associated with
large differences in frequency across Europe and unrelated with
the previous [32].
Association Analysis
We compared SNP genotype frequencies between cases positive
and negative for each of the ACR classification criteria (except
presence of ANA given that they were almost uniformly positive)
and age of disease onset. Only patients with information of at least
9 of these 11 features were included in the study (Table 1). The
comparisons were done with logistic regression following a genetic
additive model with codes 2 for aa genotypes, 1 for aA genotypes
and 0 for the AA genotypes. Possible confounding factors were
included as covariates in the regression model. These included the
17 recruiting centres as dichotomous variables with value 1 if the
sample came from that centre and 0 otherwise. We added also as
covariates the patient genotypes at the five top AIMs. In addition,
a variable with codes 1 for samples from the Iberian Peninsula and
0 from the rest of samples was added for the analysis of oral ulcers
because this is an important differential factor for this clinical
feature [30]. Results with P,0.05 at this stage were further
analyzed by stratifying by patient gender and by including as
covariate time of follow-up. Bonferroni correction for multiple
tests was applied considering the number of analyzed clinical
features. To compare our results with previous reports, samples
from collections that have participated in any of them were
excluded. These analyses were done in a customized version of
Statistica 7.0 (StatSoft, Tulsa, OK, USA).
Results
We collected DNA samples and clinical information from 1742
patients with SLE from 17 recruiting centres in 10 European
Table 1. Clinical characteristics of the patients with SLE
included in the analyses.
Features value
% available
information
Women (%) 90.5 99.4
Age at disease onset (mean, SD) 30.7 (13.0) 95.8
Time of follow-up (mean, SD) 12.0 (8.4) 83.5
Malar rash (%) 56.0 93.8
Discoid rash (%) 17.7 99.5
Photosensitivity (%) 52.2 99.9
Oral ulcers (%) 27.4 99.9
Arthritis (%) 79.0 100.0
Serositis (%) 35.3 99.9
Renal disorder (%) 41.6 100.0
Neurologic disorder (%) 14.6 94.0
Hematologic disorder (%) 72.9 97.1
Immunologic disorder (%) 77.9 99.5
doi:10.1371/journal.pone.0045356.t001
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countries. They were ascertained to have a uniform self-reported
origin from the country of recruitment and genotyped for top
AIMs informative about European population substructure. We
required for inclusion in this study that each patient should have
complete genotypes for the top AIMs and almost complete clinical
information defined as 9 or more of the following data: ACR
classification criteria, gender and age of disease onset. These
conditions were fulfilled for 1444 patients (Table 1). We had
already genotyped these samples for 26 SNPs tagging independent
SLE association signals [16,29,30], which have been identified in
other large studies (Table 2). All of them have passed our quality
control filters and most of them were significantly associated in our
samples and showed the same direction of change and a very
similar effect size than the reported in the study where they were
discovered (Table 2; and Table S1 for individual genotypes).
There were only 5 of these SNPs that were non-associated in our
samples.
In the current case-only analysis, we compared genotype
frequencies of each of the SLE SNPs between SLE patients
showing the clinical features with those not showing them. All the
analyses were adjusted for recruiting centre and for the five top
non-redundant AIMs. This is necessary because some of the
features and some of the SLE risk alleles are known to vary
between European subpopulations [17,30,33,34,35].
Renal disorder was the clinical feature showing more associa-
tion signals (Table 3). It was associated with the XKR6, FAM167A-
BLK, TNFSF4 and ICA1 SNPs. Only the effect of FAM167A-BLK
was of increased risk with the SLE risk allele. In all the others the
risk allele was protective for nephritis. All these associations
persisted after adjusting for gender and time of follow-up (Table
S2) and the two first, with XKR6 and FAM167A-BLK SNPs, were
significant after correction by the number of tests (Table 3).
Age of disease onset, either as a dichotomous or as a continuous
variable, was also nominally associated with three SLE loci
(Table 3). There was association with age at onset with the ATG5,
STAT4 and MECP2 SNPs. The association with MECP2 was the
unique association over the threshold for multiple tests. However,
special caution with this result is required because it was observed
only in men. They were analyzed separately from women because
this locus is in the X chromosome. The risk allele of ATG5 was
associated with older age of onset and the risk alleles of the other
two loci with younger onset. These association signals did not
Table 2. SNPs tagging SLE susceptibility loci with indication of their association in the study where they were discovered and in
our current samples [16,29,30].
SNP discovery study Current study
SNP Locus OR (95% CI) P Ref. OR (95% CI) P
rs2187668 HLA-DQA1 1.9 (1.7–2.2) 3.0610221 22 2.2 (1.9–2.5) 1.1610225
rs10488631 IRF5 1.7 (1.5–1.9) 1.7610211 22 2.0 (1.7–2.3) 8.4610221
rs3131379 MSH5 2.4 (2.1–2.6) 1.7610252 21 2.3 (1.9–2.7) 6.4610220
rs1143679 ITGAM 1.8 (1.6–2.0) 1.7610217 25 1.7 (1.5–1.9) 1.1610216
rs7574865 STAT4 1.5 (1.2–1.8) 2.861029 21 1.6 (1.4–1.9) 2.4610212
rs2230926 TNFAIP3 2.0 (1.4–3.0) 3.061024 24 2.0 (1.6–2.5) 2.5610210
rs729302 IRF5 0.7 (0.5–0.8) 6.761023 19 0.7 (0.7–0.8) 1.761027
rs13277113 FAM167A-BLK 1.4 (1.3–1.5) 1.1610210 22 1.3 (1.2–1.5) 5.161027
rs2304256 TYK2 0.6 (0.5–0.8) 5.661025 19 0.8 (0.7–0.9) 2.561025
rs5754217 UBE2L3 1.2 (1.1–1.3) 7.561028 21 1.3 (1.1–1.4) 7.361025
rs10798269 1q25.1 0.8 (0.8–0.9) 1.161027 21 0.8 (0.7–0.9) 1.361024
rs2205960 TNFSF4 1.3 (1.1–1.5) 7.061023 20 1.3 (1.1–1.4) 1.361024
rs844644 TNFSF4 0.7 (0.6–0.8) 6.861025 20 0.8 (0.7–0.9) 7.261024
rs17435 a MECP2 1.3 (1.1–1.5) 8.061024 26 1.3 (1.1–1.4) 8.561024
rs2476601 PTPN22 1.5 (1.3–1.8) 5.261026 21 1.3 (1.1–1.6) 9.261024
rs4963128 KIAA1542 0.8 (0.7–0.9) 3.0610210 21 0.8 (0.8–0.9) 1.161023
rs1801274 FCGRIIA 1.4 (1.2–1.5) 6.861027 21 1.2 (1.1–1.3) 1.361023
rs6920220 TNFAIP3 1.2 (1.1–1.3) 4.061027 27 1.2 (1.1–1.4) 2.361023
rs6445975 PXK 1.3 (1.2–1.4) 7.1610210 21 1.2 (1.1–1.3) 3.861023
rs573775 ATG5 1.2 (1.1–1.3) 1.461027 21 1.2 (1.1–1.3) 4.461023
rs17266594 BANK1 0.7 (0.6–0.8) 4.7610211 23 0.8 (0.7–0.9) 6.261023
rs4240671 XKR6 0.75 (0.7–0.8) 6.661029 21 0.9 (0.8–1.0) 0.11
rs10156091 ICA1 1.3 (1.2–1.5) 1.961027 21 1.1 (0.9–1.3) 0.3
rs2667978 LYN 0.8 (0.7–0.8) 5.161028 21 0.9 (0.8–1.1) 0.3
rs509749 LY9 377:403 b 2.161023 28 1.0 (0.9–1.1) 0.5
rs6922466 PERP 0.8 (0.7–0.9) 1.061024 24 1.0 (0.9–1.1) 0.8
OR: Odds ratio. CI: confidence interval.
aOnly women. The result for men in our samples was O.R. = 2.11 (1.3–3.4), P= 0.001.
bOberved:Expected in transmission disequilibrium test.
doi:10.1371/journal.pone.0045356.t002
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improve by considering age of onset in its full quantitative range
with linear regression (Table 3 and rs573775 in ATG5, P = 0.3).
The association of STAT4 with earlier SLE onset had already been
reported and with a very similar odds ratio (OR) in a study that did
not include overlapping samples with the current one [10].
None of the remaining association signals obtained with other
clinical features was over the threshold accounting for multiple
tests (Table 3). Among the weak association signals there were
three with immunological disorder: TNFSF4, LY9 and XKR6.
Neurologic disorder was nominally associated with SNPs in IRF5
and LY9, serositis with SNPs in LYN and TYK2, discoid rash with
SNPs in IRF5 and TYK2, photosensitivity with SNPs in FCGR2A
and TNFSF4, hematologic disorder with the SNP in MSH5, and
oral ulcers with the PTPN22 nsSNP. None of these nominal
associations has previously been reported. In addition, we did not
replicate any of the other previously reported associations beyond
the already commented of STAT4 with early disease onset
(Table 4). However, some of our results were concordant in
direction and magnitude as between the TNFSF4 SNP and lupus
nephritis [14], and STAT4 SNP and protection from oral ulcers or
risk to immunologic disorder [10,14].
Discussion
Our study has found that some of the SLE susceptibility loci
contribute to shape the SLE phenotype. In addition, it has shown
more associations with some clinical features than with others,
with a pattern that is reproducible and that indicates the most
productive SLE subphenotypes for future projects. Some of the
specific associations start to be consistently observed in different
studies, although our results are not strong enough to firmly
establish them. Three of the associations we have found were over
the threshold accounting for multiple tests and one replicated a
previous finding. Some of the remaining associations were also of
interest because they were concordant in direction and magnitude
with previous reports.
The clearest associations were found between renal disorder and
SNPs in the XKR6 and FAM167A-BLK loci. Both associations
remained significant after correction for multiple tests. XKR6 was
found associated with SLE in the SLEGEN GWAS with 5 SNPs
showing P,561028, although it was not highlighted because they
were not uniformly associated in the 4 sets of samples included in
that study [21]. There has been independent replication of one of
the SNPs in a subsequent study [36]. The SNP reported here was
not associated with SLE in our samples (Table 2), and none of the
XKR6 SNPs were associated in the largest attempt to replicate SLE
GWAs results [27]. Therefore the status of this locus in SLE
susceptibility is still uncertain. We are not aware of any previous
attempt to explore association between SNPs in this gene and SLE
clinical features. The XKR6 gene codes for one of the transmem-
brane proteins of the Kell blood group of antigens expressed in red
blood cells, although it is also expressed in other tissues. Its possible
role in SLE is completely unclear because almost nothing is known
about this protein.
Association between lupus nephritis and the SLE risk allele of
rs13277113 in the FAM167A-BLK locus remained significant after
correcting for the number of tests, and was consistently observed in
women and men. The same SNP has already been analyzed for
association with SLE classification criteria in two previous
overlapping studies [14,22], but no association with renal
involvement was found. A third overlapping study analyzed a
different SNP with the same result [13]. As these previous studies
are very large, the association we have found should be considered
only as tentative.
The third significant association in our study was found between
earlier age at disease onset and the risk allele of the MECP2 SNP.
This association should be taken with special caution because it
was restricted to men and there were only 137 men with SLE
among our patients.
Other signals of association were found, but none was
significant after correction for multiple tests. Overall the associ-
ations seem to concentrate in some clinical features: renal disorder,
age at onset and immunological disorder are the clearest. In
contrast, there are clinical phenotypes that did not appear in any
analysis, like malar rash or arthritis. This is in agreement with
previous reports where also renal disorder, different types of
autoantibodies and age of disease onset are prominent
[9,10,11,12,13,14].
Replication of the association of individual locus with specific
SLE phenotypes was only obtained for the previous association
between STAT4 and early age of disease onset [10]. Our study was
completely independent from the original study and, therefore, it
constitutes formal replication. In addition, our results showed
some trends that followed the same direction observed in previous
reports. The clearest examples are the associations of a TNFSF4
SNP with lupus nephritis [14], and the protection conferred by
Table 3. SLE clinical characteristics showing association with
SLE susceptibility SNPs.
Feature SNP Locus P OR (95% CI) Pcorr
Renal disorder rs4240671 XKR6 0.0006 0.76 (0.7–0.9) 0.007
rs13277113 FAM167A-BLK 0.003 1.30 (1.1–1.5) 0.03
rs10156091 ICA1 0.03 0.76 (0.6–1.0) 0.3
rs844644 TNFSF4 0.04 0.85 (0.7–1.0) 0.4
Disease
onset ,30
rs573775 ATG5 0.005 0.78 (0.7–0.9) 0.06
rs7574865 STAT4 0.03 1.20 (1.0–1.4) 0.3
rs17435 MECP2 a 0.003 1.92 (1.2–3.0) 0.03
Disease onset
full range
rs7574865 STAT4 0.02 21.21 (22.2
20.2)b
0.2
rs17435 MECP2 a 0.02 23.57 (26.6
20.5)b
0.3
Immunologic
disorder
rs2205960 TNFSF4 0.01 1.39 (1.1–1.8) 0.1
rs509749 LY9 0.01 1.31 (1.1–1.6) 0.2
rs4240671 XKR6 0.04 0.81 (0.7–1.0) 0.5
Neurologic
disorder
rs10488631 IRF5 0.01 0.64 (0.5–0.9) 0.1
rs509749 LY9 0.04 1.26 (1.0–1.6) 0.4
Serositis rs2667978 LYN 0.02 0.79 (0.7–1.0) 0.2
rs2304256 TYK2 0.03 1.23 (1.0–1.5) 0.3
Discoid rash rs729302 IRF5 0.02 0.75 (0.6–1.0) 0.2
rs2304256 TYK2 0.03 1.29 (1.0–1.6) 0.3
Photosensitivity rs1801274 FCGRIIA 0.03 1.19 (1.0–1.4) 0.3
rs2205960 TNFSF4 0.03 1.22 (1.0–1.5) 0.3
Hematologic
disorder
rs3131379 MSH5 0.03 1.37 (1.0–1.8) 0.3
Oral ulcers rs2476601 PTPN22 0.04 0.72 (0.5–1.0) 0.5
aMen only.
bCoefficient of the linear regression.
doi:10.1371/journal.pone.0045356.t003
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STAT4 for oral ulcers [10,14]. For these two comparisons, our
results showed the reported direction of change but they were not
significant, specially when the samples overlapping between our
study and the Sanchez et al. study [14] were excluded. These
coincidences are encouraging and they give further motivation for
additional studies.
Unfortunately, lack of replication of association results regard-
ing clinical phenotypes is still very common. For example, in two
large studies there were 8 claims of association (5 plus 3,
respectively), but none was coincident in spite of overlap between
the samples [13,14]. Probably, these results, as well as ours, are
reflection of two types of obstacles. The first is related with the
studied loci because a weak phenotype specificity of these loci is
implied in the fact that they have been identified in studies
involving a wide spectrum of patients with SLE. This circumstance
makes it likely that many SNPs with association to particular SLE
features will be missing from the list of SLE susceptibility loci. This
is exemplified by the FCGR3A V158F polymorphism that is
associated with lupus nephritis, but not with SLE susceptibility
overall [37]. Therefore, it is likely that phenotype-specific GWAs
will be more informative. As a first step, a reanalysis of the
available GWAs stratified by clinical features could provide useful
leads. The second type of obstacles is due to the analysis of
subphenotypes, which are highly variably between patients,
centres and ethnic groups [10,17,22,34,35,38,39,40,41]. To
account for these factors, we have restricted our analyses to
subjects of European ancestry and we have adjusted our results for
centre of recruitment and for AIMs informative of population
substructure. These are precautions that have not been used
uniformly in the studies of this type. However, it is not possible
through analysis to recover the lost statistical power due to
variability between the collections and division of the available
data in strata. These properties of the analysis of subphenotypes
are typical of any subgroup analysis and make replication of results
more difficult [42].
In spite of the difficulties and that these are still early times for
these studies; there are results that start to be consistent. They
include the concordances we have already signalled relating
STAT4 with earlier disease onset or oral ulcers [10,14]. Also,
encouraging are the results relative to the association of ITGAM
with nephritis, which has already been reported in four studies and
that showed the same direction in our samples [11,12,14,15]. A
clinical characteristic not included in the current study, the
production of anti-dsDNA, has also shown reproducible associa-
tion with some SLE loci [9,10,13].
Conclusion
In summary, we have found some new genetic associations with
SLE clinical features among the SLE susceptibility loci. They
confirm the hypothesis that some of these loci shape the SLE
phenotype in addition to increase susceptibility to the disease. Our
results also support a gradation in the clinical features showing
association with these loci: with lupus nephritis, immunologic
disorder and age of onset showing the most numerous and clear
associations. There were three new associations, XKR6 and
FAM167A-BLK with lupus nephritis and MECP2 with early onset
of SLE in men, which need to be taken with caution because either
they have never been explored before, or they were not found in
previous studies. Replication of the association between early age
of disease onset and STAT4 was obtained. Results for other specific
associations showed consistency with previous results without
amounting to replication. Overall, results in this field show the
need to start GWAS specific for SLE subphenotypes either by
reanalysis of existing data or through new studies. A prime
candidate for these studies is renal disorder because of its clinical
relevance and its prominent association with known SLE loci.
Supporting Information
Table S1 Individual genotypes for the 26 SNPs tagging
SLE loci in the patients included in the study. Sex,
0 = male; 1 = female; genotypes, 0 = AA, 1 = Aa and 2 = aa.
(XLS)
Table S2 SLE clinical characteristics showing associa-
tion with SLE susceptibility SNPs including data adjust-
ed by gender and time of follow-up. aThis result is only for
Table 4. Comparison of previous significant SLE subphenotype associations in case-only analysis with our results regarding the
same SNPs.
Previous studies Current study
Feature SNP Locus OR (95% CI) P Ref. OR (95% CI) P
Renal disorder rs2205960 TNFSF4 1.18 (1.1–1.3) 0.003 14 1.16 (0.9–1.5)a 0.2a
rs1143679 ITGAM 1.39 (1.2–1.7) 0.0003 11 1.13 (0.9–1.4) 0.2
rs7574865 STAT4 1.23(1.0–1.5) 0.02 10 0.91 (0.8–1.1) 0.3
rs2187668 HLA-DQA1 1.37 (1.1–1.6) 0.0006 13 1.03 (0.9–1.2) 0.8
Disease onset ,30 rs7574865 STAT4 1.22 (1.0–1.4) 0.02 10 1.20 (1.0–1.4) 0.03
Immunologic disorder rs7574865 STAT4 1.24 (1.0–1.5) 0.02 10 1.16 (0.9–1.5) 0.2
rs1143679 ITGAM 1.30 (1.0–1.7) 0.04 11 1.10 (0.8–1.4) 0.5
rs4963128 KIAA1542 0.79 (0.7–0.9) 0.002 13 0.98 (0.8–1.2) 0.9
Oral ulcers rs7574865 STAT4 0.80 (0.7–0.9) 0.009 10 0.84 (0.7–1.0) 0.07
Malar rash rs1801274 FCGRIIA 1.14 (1.0–1.3) 0.01 14 1.10 (0.9–1.3)a 0.4 a
Hematologic disorder rs13277113 FAM167A-BLK 1.23 (1.0–1.5) 0.02 22 1.07 (0.9–1.3) 0.5
Discoid rash rs1143679 ITGAM 1.27 (1.0–1.6) 0.02 11 1.01 (0.8–1.3) 0.9
aOR (95% CI) and P values calculated excluding patients from The Netherlands, Germany, Belgium, Hungary, Asturias (Spain), Rome (Italy) and Naples (Italy) which
overlapped with the used in [14] under the BIOLUPUS collection.
doi:10.1371/journal.pone.0045356.t004
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men and therefore the adjustment has been made only for time of
follow-up.
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